Quick search
Advanced search in
Field to searchTerm
Add rule
Download Results
211 research outcomes, page 3 of 22
  • publication . Article . 2019
    Open Access Russian
    Authors:
    Semenova, A. A.; Zeynalova, P. A.; Nikitina, M. S.; Akhmedov, M. I.;
    Persistent Identifiers
    Publisher: ABV-press

    The introduction of new monoclonal antibodies has become an integral part of the treatment of malignant tumors.Brentuximab vedotin (Adcetris®) – anti-D30 monoclonal antibody conjugated with monomethyluristatin E – has become a new drug registered since February 2016 in ...

    Add to ORCIDorcid
  • publication . Article . 2015
    Open Access Russian
    Authors:
    Volodin, N. N.; Kasatkin, V. N.; Tseitlin, G. Ya.; Sidorenko, L. V.; Mironova, E. V.; Mitrakov, N. N.; Miroshkin, R. B.; Shcheglova, D. D.; Rumyantsev, A. G.;
    Persistent Identifiers
    Publisher: ABV-press

    Advances in the treatment of children with hematological and oncological diseases have led to accumulation of disabled children with severe organic and functional disorders that require the development of medical, neurocognitive, physical and psycho-social rehabilitatio...

    Add to ORCIDorcid
  • publication . Article . 2019
    Open Access Russian
    Authors:
    M. A. Kislitsyna; T. N. Obukhova; A. V. Kokhno; L. A. Grebenyuk; A. V. Luchkin; L. A. Kuzmina; V. N. Dvirnyk; A. M. Kovrigina; I. V. Galtseva; B. V. Biderman; ...
    Persistent Identifiers
    Publisher: ABV-press

    In chronic lymphocytic leukemia, the risk of second tumors including hematological malignancies, with which the use of purine nucleosides and alkylating agents in treatment of chronic lymphocytic leukemia is most often associated, is significantly increased. Concurrent ...

    Add to ORCIDorcid
  • publication . Article . 2019
    Open Access
    Authors:
    Rekhtina, I. G.; Mendeleeva, L. P.;
    Persistent Identifiers
    Publisher: Publishing House ABV Press

    Currently, there has been a marked increase in the number of opportunities for relapsed and refractory multiple myeloma treatment due toemergence of new target drugs. These include pomalidomide, a 3rd generation immunomodulator capable of treating double refractory mult...

    Add to ORCIDorcid
  • publication . Article . 2019
    Open Access Russian
    Authors:
    Golovkina, L. L.; Kalandarov, R. S.; Pshenichnikova, O. S.; Surin, V. L.; Stremoukhova, A. G.; Pushkina, T. D.; Khasigova, B. B.;
    Persistent Identifiers
    Publisher: ABV-press

    Background. Rhesus phenotype has been determined in 404 persons which have problems with blood groups identification. Genetic typing of antigen RhD variants was performed in 73 individuals. Objective of the work was to give molecular and serological characteristics of t...

    Add to ORCIDorcid
  • publication . Article . 2018
    Open Access
    Authors:
    Solov’eva, A. A.; Yatsyk, G. A.; Dzhulakyan, U. L.; Lukina, E. A.;
    Persistent Identifiers
    Publisher: Publishing House ABV Press

    Storage diseases (thesaurismosis, storage reticuloses) are the complex and extensive group of diseases in which differential diagnosis of pathological changes from the internal organs is difficult. For diagnosis and dynamic observation of liver and spleen lesions, ultra...

    Add to ORCIDorcid
  • publication . Article . 2018
    Open Access
    Authors:
    Valiev, T. T.;
    Persistent Identifiers
    Publisher: Publishing House ABV Press

    Despite the development and active use of modern high-effective therapeutic protocols for pediatric non-Hodgkin’s lymphomas (NHL), treatment results of relapses and refractory disease are unsatisfactory. In the current issue international practices and own experience in...

    Add to ORCIDorcid
  • publication . Article . 2015
    Open Access Russian
    Authors:
    A. N. Khvastunova; L. S. Al-Radi; N. M. Kapranov; O. S. Fedyanina; L. A. Gorgidze; S. A. Lugovskaya; E. V. Naumova; U. L. Dzhulakyan; A. V. Filatov; F. I. Ataullakhanov; ...
    Persistent Identifiers
    Publisher: ABV-press

    We describe an application of a cell-binding microarray – to parallel study of morphology, tartrate-resistant acid phosphatase activity and detection of surface markers on peripheral blood lymphocytes of 90 atients with suspected hairy cell leukemia (HCL). We have formu...

    Add to ORCIDorcid
  • publication . Article . 2019
    Open Access Russian
    Authors:
    Anna Petrova; E Yu Chelysheva; Anna G. Turkina;
    Persistent Identifiers
    Publisher: ABV-press

    Tyrosine kinase inhibitors have radically changed the course of chronic myeloid leukemia, significantly increasing survival and reducing the risk of disease progression. Nearly 50–70 % of patients achieve a consistently low or undetectable level of minimal residual dise...

    Add to ORCIDorcid
  • publication . Article . 2018
    Open Access Russian
    Authors:
    Volchkov, E. V.; Zharkov, P. A.; Panteleev, M. A.;
    Persistent Identifiers
    Publisher: ABV-press

    Ibrutinib, an irreversible Bruton tyrosine kinase inhibitor (Btk), is a highly effective drug for treatment a number of B-cell lymphoproliferative disorders and, more recently, graft-versus-host disease. However, a number of potentially adverse events are possible in th...

    Add to ORCIDorcid
211 research outcomes, page 3 of 22